Intellia Therapeutics Inc

NASDAQ:NTLA   3:59:58 PM EDT
131.70
-2.51 (-1.87%)
Products, Regulatory

Intellia Therapeutics Inc Receives Authorization To Initiate Phase 1/2 Clinical Trial Of NTLA-2002

Published: 10/06/2021 11:44 GMT
Intellia Therapeutics Inc (NTLA) - Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-2002 for Treatment of Hereditary Angioedema.
Intellia Therapeutics Inc - on Track to Initiate Patient Enrollment by Year-end.
Intellia Therapeutics- Submitting Additional Regulatory Applications in Other Countries As Part of Its Ongoing, Development Approach for Ntla-2002.